Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC

INTRODUCTION: Biological therapies such as bevacizumab have improved survival in patients with NSCLC. This study was conducted to confirm the equivalent efficacy of the biosimilar candidate BI 695502 to the bevacizumab reference product (RP). METHODS: In this phase 3, multicenter, randomized, double...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Edward S., Balser, Sigrid, Rohr, Klaus B., Lohmann, Ragna, Liedert, Bernd, Schliephake, Dorothee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713120/
https://www.ncbi.nlm.nih.gov/pubmed/34993498
http://dx.doi.org/10.1016/j.jtocrr.2021.100248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713120/
https://www.ncbi.nlm.nih.gov/pubmed/34993498
http://dx.doi.org/10.1016/j.jtocrr.2021.100248

Ejemplares similares